Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
New Data at AACR Showcase Reaction Biology's Innovative Approach to Oncology Drug Discovery Services
Details : Adavosertib (AZD1775, MK-1775), a clinical-stage inhibitor of tyrosine kinase WEE1, exhibited a broad anti-cancer activity across all hematological and solid tumor types with IC50 values ranging from 0.06 to 10 µM, matching consistently high expression...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable